Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

PREVENTION BY MAGNESIUM OF EXOTOTOXIC NEURONAL DEATH IN THE DEVELOPING BRAIN: AN ANIMAL MODEL FOR CLINICAL INTERVENTION STUDIES

Manet, Stephane, Gressens, Pierre, Gadisseux, Jecin‐Frtinçois, Evrard, Philippe · 1995 · Developmental Medicine & Child Neurology

Abstract

SUMMARY: Excitotoxic disturbances during brain development were studied in the mouse using intracerebral injections of ibotenate, a glutamatergic agonist of the N‐methyl‐D‐aspartatc (NMDA) complex receptor, to analyse the protective effect of a systemic bolus of MgSO 4. a non‐competitive antagonist of the NMDA ionophore‐complex receptor. MgSO 4 did not prevent microgyia, induced by ibotenate when injected at PO immediately after the post‐migratory settlement of layer V, but did prevent ulegyrias. porencephalic cysts, and other cortical and cortical subcortical hypoxic‐like lesions arising after completion of the neocortical cyto‐architectonic development at P5. Protection was optimal in 80 per cent of mice at 600mg/kg. with no mortality due to MgSO 4: thereafter mortality increased with dosage. The protective effect appears after the developmental acquisition of two properties of the excitotoxic cascade, namely the coupling of the massive calcium influx with NMDA‐receptor overstimulation and the predominance of magnesium‐oblilerable calcium channels. This animal model supports the clinical intervention studies with magnesium in hypoxias/perfusion failures and has implications for their design. If maturation of the excitotoxic cascade follows the same sequence in humans, protection is probably low before 26 weeks of gestational age. RÉSUMÉ: Prévéntion de la mart ncuronali excitotoxique par le magnésium dans le cerveau en développement Lees lesions excilotoxiques ont étéétudiées duranl le développement cérébral de la souris à lcar;aide dcar;injections intracerebrales dcar;iboténate, un agoniste glutaminergique des récepieurs ionotropiques de type N‐méthyl‐D‐aspartate (NMDA). pour évaluer lcar;effet protecteur dcar;une dose de sulfate de magnésium, un antagoniste non competitif du rccepteur NMDA. CheZ, la souris, le sulfate de magnésium n'empěche pas la survenue de microgyrie induite par lcar;ibotenate quant il est injectéà la naissance. immediatement aprés la mise en place ct la maturation des neurones des couches corticales V et Via. Par eontre. le magnésium empéche les ulégyries, les kystes porencéphaliques et les autres lésions corticales et sous‐corticales de type hypoxique. induils par lcar;injeclion dcar;ibotenate au cinquième jour postnatal aprés la fin du développement cyto‐architectonique néocortical. La protection était optimale chez 80 pour cent des animaux à 600 mg/kg de sulfate de magnésium, sans mortalité secondaire; la mortalité augmente ensuite avec les doses. lcar;effet protecteur apparait aprés lcar;acquisition de deux propriélés de la cascade excitotoxique. le couplage de lcar;linflux calcique massif avec line stimulation excessive des récepteura el lcar;acquisition dcar;une sensibililé du récepteur NMDA à lcar;effet du magnésium. Ce modéle animal justilie les éludes cliniques multicentriques utihsant le magnésium dans les hypoxies/ischémiques du nouveau‐né a terme. Si la maturation de la cascade excitotoxique est similairc dans lcar;espéce humaine, lcar;effet protecteur du magnesium est probablement limitée avant 26 semaines. ZUSAMMENFASSUNG: Verhinderung des excitotoxischen Ncuronentodes ini sich enlwtck‐Gehirn durch Magnesium Bei der Maus wurden excitotoxische Storungen im Verlauf der Hirnentwicklung durch intracerebrale Injekjtionen von Ibotenat. eines glutamaterger Agonisten des N‐Methyl‐D‐Aspartat (NMDA) Rezeptors, untersucht. um den protektiven I‐IHckt eines systemischen Bolus von MgSO‐. eines nicht Ikompetitiven Antagonisien des NMDA lonoplioren‐Komplex Re/eptors, zu analysicren MgSO' verhinderle die durch Ibotenat indu/ierte Mikrogyne nicht wenn es bei PO sofort nach der posimigratorischen Bildung der Schieht V injiziert wurde, aber es verhinderle Ulegynen, porenzephale' Zsten. und andere corticale und cortico‐stibcorticale Läsionen wie bei Hypoxic die nach Beendigung der neocorticalen cyto‐architcktonischen Entwicklung bei P5 auftreten. Mit einer Dosis von 600 mg/kg war der Schutz bei 80 Prozenl der Tiere optimal, ohne Todesfälle durch MgSO; dauach stieg die Mortalität mit der Dosis. Die protektive Wirkung trilt erst nach der Entwicklung von zwei Kigensehaften der excitotoxischen Cascade auf, nämlich die Verbindung eines massiven Calzium Einstroms in die Zelle bei Uberstimulation des NMDA Rezeptors und das Uberwiegen von durch Magnesium blockierbaren Calcium Kanälen. Dieses Tierniodcil beslätigt die Berechtigung klinischer Interventionsstudien mit Magnesium bei Hypoxien und Perfusionsstörungen und ist für die Planing solcher Studied von Bedeutung. Sollte die Reifung der excitotoxischen Cascade beim Menschen in der gleichen Weise ablaufen, dann ist die protewktive Wirkung von Magnesium wahrscheinlich niedrig bei einer Schwangerschaftsdauer von weniger als 26 worden. RESUMEN: Prcvcinion con magnesio de la mucrle neuronal excitortixs en e I i cerecbro en desaorollo. Se estudió en le ratón las alteruciones exeilotóxicas durante el desarrollo cerebral, utilizando inyecciones intracerebrales de ibotenate, un agonista glutaminergico de receptor complejo N‐melil‐D‐aspartato (NMDA). con el objeto de analizar el efecto protecto de un sistema bolus de MgSO‐. un antagonista no competitive de receptor ionoforo‐complejo NMDA. HI MgSO‐ no previno la microgiria. inducida por ibotenato cuan do se inyeció inmediatamente después del eslablecimiento postmigraiorio de la capa V. pcro sí previno ulegirias. quisles porencefálicos y otras lesiones corticales y subcorticales de tipo hipóxico. aparecidas después de conipletar.se el desarrollo neocortical cito‐arquitectónico a nivel P5. La protección tue óptima en el 80 por ciento de los animalcs a razón de 600 mg/kg, sin Imortalidad debida al MgSO'. la muetalidad aumentó con la dosis. El efecto protector aparece después del desarrollo de dos propiedades de la cascada excitotóxica, a saber: el acoplamiento de intlujo cálcico masivo con sobreestitnulación de receptor NMDA ly la prcdominancia de los canales cálcicos con magnesio en fallos de hipoxia‐pertusión y tiene implicaciones pani sn discño. Si hi maduración de la cascada excitotóxica sigue las misinas secucncias en los humanos, la prolección es probablenientc baja antes de las 26 scnianas de edad gestational.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-8749.1995.tb12035.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 172

Metadata

Authors
Manet, S., Gressens, P., Gadisseux, J., & Evrard, P.
Venue
Developmental Medicine & Child Neurology
Publisher
Wiley
Published
1995-06
Volume
37
Issue
6
Pages
473-484
ISSN
  • 0012-1622 (ISSN-L)
  • 1469-8749
OpenAlex
W2097568439
Cited by
172
References
2
FWCI
13.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PREVENTION BY MAGNESIUM OF EXOTOTOXIC NEURONAL DEATH IN THE DEVELOPING BRAIN: AN ANIMAL MODEL FOR CLINICAL INTERVENTION STUDIES. https://app.cochat.ai/papers/10.1111/j.1469-8749.1995.tb12035.x
The paper
Manet, S., Gressens, P., Gadisseux, J., & Evrard, P. (1995). PREVENTION BY MAGNESIUM OF EXOTOTOXIC NEURONAL DEATH IN THE DEVELOPING BRAIN: AN ANIMAL MODEL FOR CLINICAL INTERVENTION STUDIES. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.1995.tb12035.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.